| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 258,482 | - |
| Cost of sales - product | 42,207 | - |
| Research and development | 55,112 | - |
| Selling and marketing | 70,199 | - |
| General and administrative | 67,924 | - |
| Other segment items | 73,491 | - |
| Net (loss) income | -50,451 | -77,378 |
| Depreciation and amortization | 3,706 | 2,415 |
| Amortization of right-of-use assets | 2,463 | 1,660 |
| Inventory write off | 3,638 | 3,976 |
| Sublease termination loss (note 5) | 0 | 0 |
| Accretion of discounts on marketable securities | 5,034 | 3,835 |
| Stock-based compensation expense | 39,824 | 27,434 |
| Bad debt expense | 10,970 | 10,970 |
| Non-cash interest expense | 820 | 3,333 |
| Loss on debt extinguishment | -82,095 | -82,095 |
| Accounts and other receivables, net | 26,415 | 26,439 |
| Inventories | 6,872 | 9,609 |
| Prepaid manufacturing | 0 | - |
| Prepaid expenses and other current assets | 2,260 | 5,595 |
| Other assets | 0 | - |
| Accounts payable | -5,148 | -6,503 |
| Lease liabilities | -3,151 | -2,152 |
| Accrued and other liabilities | -6,564 | 3,420 |
| Net cash provided by operating activities | 37,621 | 3,792 |
| Purchases of marketable securities | 251,655 | 111,793 |
| Proceeds from maturities and redemption of marketable securities | 387,297 | 218,875 |
| Purchases of property and equipment, net | 6,617 | 5,380 |
| Net cash provided by (used in) investing activities | 129,025 | 101,702 |
| Proceeds from issuance of convertible notes (note 7) | 39,708 | 39,708 |
| Payment for debt issuance costs (note 7) | 4,500 | 4,500 |
| Payments for debt extinguishment (note 7) | 80,938 | 80,938 |
| Proceeds from unwind of capped call options (note 7) | 46,554 | 46,554 |
| Payments for repurchase of common stock (note 11) | 101,207 | 100,635 |
| Proceeds from exercise of stock options | 6,833 | 6,738 |
| Proceeds from employee stock purchase plan | 1,499 | 835 |
| Payments for taxes related to net share settlement of restricted and performance stock units | 11,810 | 11,562 |
| Net cash used in financing activities | -103,861 | -103,800 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 1,613 | 1,558 |
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 64,398 | 3,252 |
| Cash and cash equivalents at beginning of period | 96,154 | - |
| Cash and cash equivalents at end of period | 160,552 | - |
DYNAVAX TECHNOLOGIES CORP (DVAX)
DYNAVAX TECHNOLOGIES CORP (DVAX)